Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Return on Invested Capital (2020 - 2025)

Nurix Therapeutics (NRIX) has disclosed Return on Invested Capital for 5 consecutive years, with 0.63% as the latest value for Q4 2025.

  • Quarterly Return on Invested Capital fell 16.0% to 0.63% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.63% through Nov 2025, down 16.0% year-over-year, with the annual reading at 0.54% for FY2025, 5.0% up from the prior year.
  • Return on Invested Capital for Q4 2025 was 0.63% at Nurix Therapeutics, up from 0.65% in the prior quarter.
  • The five-year high for Return on Invested Capital was 0.28% in Q1 2021, with the low at 0.85% in Q1 2024.
  • Average Return on Invested Capital over 4 years is 0.5%, with a median of 0.5% recorded in 2025.
  • The sharpest move saw Return on Invested Capital crashed -65bps in 2021, then soared 39bps in 2025.
  • Over 4 years, Return on Invested Capital stood at 0.33% in 2021, then plummeted by -73bps to 0.57% in 2022, then rose by 17bps to 0.47% in 2024, then crashed by -33bps to 0.63% in 2025.
  • According to Business Quant data, Return on Invested Capital over the past three periods came in at 0.63%, 0.65%, and 0.5% for Q4 2025, Q3 2025, and Q2 2025 respectively.